Six genes (GATS, ARID3B, ASNS, FBN2, SLC27A5, and STC2) were overexpressed in the patients sensitive (defined as tumor volume decrease of approximately 70% after chemotherapy) to iCHT, while four genes (PRIC285, CXCR1, INMT, and MYOM3) were overexpressed in the non-sensitive (defined as the tumor volume decrease by less than approximately 25%) patients and the differences were statistically significant. This evidence concerns the gene STC2 and neoplasm.